8 hours ago
Addressing Partial Treatment Response in MDD Patients
About one third of patients with major depressive disorder (MDD) achieve only a partial response to antidepressant therapy. This often leaves them with symptoms that could lead to an inability to enjoy life, poor work and cognitive performance, impairment in psychosocial activities, and even suicidal ideation.
Dr George Papakostas, from Harvard Medical School, discusses the option of adjunctive therapy to improve symptom control for these patients.
He details how atypical antipsychotic drugs such as aripiprazole, brexpiprazole, cariprazine, olanzapine, and quetiapine can be added to antidepressant therapy to better control symptoms.
The VAST-D study, he reports, showed that use of an atypical antipsychotic as adjunctive therapy was found to be superior to switching antidepressants in patients who had not experienced sufficient symptom improvement with antidepressant therapy alone.
Dr Papakostas also explains how combining antidepressants such as bupropion and mirtazapine can sometimes be an effective strategy in certain patients who have partial response to antidepressant monotherapy.
